The combination of the VEGF inhibitor bevacizumab with the EGFR inhibitor erlotinib in recurrent/metastatic squamous cell carcinoma of the head and neck is under phase 1 and 2 clinical trials [75]. This evidence concerns the gene EGFR and squamous cell carcinoma.